UPLOAD Filing
ACTUATE THERAPEUTICS, INC.
Date: Aug. 26, 2025 · CIK: 0001652935 · Accession: 0000000000-25-009111
AI Filing Summary & Sentiment
Reasoning
Letter
Re: Actuate Therapeutics, Inc. Draft Registration Statement on Form S-3 Submitted August 18, 2025 CIK No. 0001652935 Dear Daniel Schmitt:
August 26, 2025
Daniel Schmitt President and Chief Executive Officer Actuate Therapeutics, Inc. 1751 River Run, Suite 400 Fort Worth, Texas 76107
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Janet Spreen, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> August 26, 2025 Daniel Schmitt President and Chief Executive Officer Actuate Therapeutics, Inc. 1751 River Run, Suite 400 Fort Worth, Texas 76107 Re: Actuate Therapeutics, Inc. Draft Registration Statement on Form S-3 Submitted August 18, 2025 CIK No. 0001652935 Dear Daniel Schmitt: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Janet Spreen, Esq. </TEXT> </DOCUMENT>